Belrestotug is under clinical development by ITeos Therapeutics and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Belrestotug’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EOS-448 is under development for the treatment of solid tumors, hematological malignancies, non-small cell lung cancer, squamous non-small cell lung cancer, relapsed or refractory multiple myeloma, PD-1 resistant melanoma and head and neck cancer squamous cell carcinoma. It is administered through intravenous route. The drug candidate is a checkpoint blocking antibody acts by targeting TIGIT.
ITeos Therapeutics overview
iTeos Therapeutics is a clinical-stage biopharmaceutical company. It discovers and develops immuno-oncology drugs for cancer. The company’s major pipeline products are EOS-448, EOS-984, dostarlimab, iberdomide, pembrolizumab, CD96 drug candidates. Its products are used to treat various cancers like advanced malignancies, relapsed refractory multiple myeloma. The drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations. Its service includes to carries out clinical trials for inupadenant, an A2A receptor antagonist, as a treatment for solid tumors in monotherapy. It has operational presence in the US; and Belgium. iTeos Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Belrestotug’s drug-specific PTSR and LoA scores, buy the report here.